Earnings Report - Abbott Laboratories is set to release its fourth-quarter earnings on January 22, with expected earnings of $1.49 per share, an increase from $1.34 per share in the same period last year [1] - The consensus estimate for Abbott's quarterly revenue is $11.8 billion, up from $10.97 billion reported last year [1] Recent Developments - On January 20, Abbott received CE Mark approval for the TactiFlex™ Duo Ablation Catheter, aimed at treating patients with abnormal heart rhythms [2] - Following this news, Abbott's shares fell by 0.3%, closing at $120.73 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained an Outperform rating and raised the price target from $150 to $154 [3] - Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $162 to $169 [3] - BTIG analyst Marie Thibault maintained a Buy rating with a price target of $145 [3] - Raymond James analyst Jayson Bedford maintained an Outperform rating and raised the price target from $141 to $146 [3] - Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating but reduced the price target from $144 to $142 [3]

Strong Q4 Results: Growth Accelerates as Profits Improve In the fourth quarter of 2025, Johnson & Johnson delivered a solid set of results that showed both steady growth and improving profitability. Revenue rose 9.1% from a year earlier to $24.56 billion, while net earnings jumped to $5.12 billion, reflecting stronger operating performance and easier comparisons. Earnings per share came in at $2.10 on a reported basis and $2.46 on an adjusted basis, highlighting healthy underlying momentum. Sales growth of ...

Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].

Flash | 21 Jan 2026 12:02:50 ET │ 11 pages MicroPort MedBot (2252.HK) FY25 Profit Alert with Strong Topline Growth; Landmark Policy Unlocks Commercialization; Reiterate Buy CITI'S TAKE MicroPort MedBot issued a strong positive profit alert for FY25, guiding for revenue growth of 110-120% YoY, beating our 100% estimate and VA consensus of 94%. The adjusted net loss is guided to narrow by more than 50%, in line with expectations. We view the topline beat as the key takeaway, as it confirms the company is in a ...

Company Developments - PAVmed Inc. (NASDAQ:PAVM) experienced a stock price surge to $16.12, marking a 160.42% increase, driven by a contract secured by its subsidiary, Lucid Diagnostics, with the U.S. Department of Veterans Affairs for the EsoGuard® Esophageal DNA Test [1][7] - Namib Minerals Ordinary Shares (NASDAQ:NAMM) saw a 145.95% increase in stock price to $2.41, with a trading volume of 103,136,334, indicating heightened investor interest possibly due to strategic developments or metal price fluctuations [2][7] - Global Interactive Technologies, Inc. (NASDAQ:GITS) reported a 93.32% rise in stock price to $1.66, reflecting growing investor interest in tech and entertainment platforms, particularly those related to K-POP and modern Korean culture [3][7] - Lisata Therapeutics, Inc. (NASDAQ:LSTA) experienced an 87.27% increase in stock price to $4.04, suggesting positive market reception for its focus on cellular therapies, despite ongoing investigations into the company [4][7] - Namib Minerals Warrants (NASDAQ:NAMMW) saw a 66.78% increase in price to $0.15, indicating investor optimism in leveraging warrants for potential gains in the mining sector [5][7] Market Dynamics - The significant price changes across these companies reflect diverse sector interests, including healthcare, biotechnology, technology, and basic materials, driven by factors such as innovative product pipelines and strategic company developments [6]

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Beta Bionics i ...

ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 millio ...

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to support its continued gr ...

Media Contact Steve Monroe VP, Financial Planning & Analysis, Accuray [email protected] SOURCE Accuray Incorporated About Accuray Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation ...

Key Takeaways BD received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System.BDX plans an early 2026 launch, offering a multi-modality platform to improve flexibility and workflow.The system supports early detection with precision features designed to enhance confidence.Becton, Dickinson and Company(BDX) , popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. Anticipated to launch ...